Palmitoyl Tripeptide-1 vs BPC-157
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Palmitoyl Tripeptide-1
Palmitoyl Tripeptide-1 (Pal-GHK) is a lipopeptide that stimulates collagen production. It's one of two peptides in the Matrixyl 3000 complex, working synergistically with Palmitoyl Tetrapeptide-7.
Full details →BPC-157
Body Protection Compound-157 is a synthetic peptide derived from a protein found in human gastric juice. It has shown remarkable healing properties in research studies.
Full details →Side-by-Side Comparison
| Aspect | Palmitoyl Tripeptide-1 | BPC-157 |
|---|---|---|
| Mechanism | Mimics the skin's own mechanism for producing collagen by acting as a messenger peptide that signals fibroblasts to produce more collagen and other extracellular matrix components. | BPC-157 works through multiple pathways including upregulation of growth factor expression, nitric oxide system modulation, and promotion of angiogenesis. It enhances tendon-to-bone healing and supports the formation of new blood vessels. |
| Typical Dosage | Topical: Typically 2-4% in serums, often combined with Palmitoyl Tetrapeptide-7 as Matrixyl 3000. | Typical research dosages range from 250-500mcg administered 1-2 times daily. Both subcutaneous and oral administration have been studied. |
| Administration | Topical application 1-2 times daily. The palmitoyl group enhances skin penetration compared to non-lipidated versions. | Can be administered subcutaneously near the injury site or systemically. Stable in gastric juice, making oral administration viable. |
| Side Effects | Very well-tolerated. Suitable for most skin types including sensitive skin. | Generally well-tolerated in research. Some reports of mild nausea or dizziness at higher doses. |
| Best For |